Research article Special Issues

Dynamics of SARS-CoV-2 infection model with two modes of transmission and immune response

  • In this paper, we propose a new within-host model which describes the interactions between SARS-CoV-2, host pulmonary epithelial cells and cytotoxic T lymphocyte (CTL) cells. Furthermore, the proposed model takes into account the lytic and nonlytic immune responses and also incorporates both modes of transmission that are the virus-to-cell infection through extracellular environment and the cell-to-cell transmission via virological synapses. The well-posedness of the model as well as the existence of equilibria are established rigorously. Moreover, the dynamical behaviour of the model is further examined by two threshold parameters, and the biological aspects of the analytical results are further presented.

    Citation: Khalid Hattaf, Noura Yousfi. Dynamics of SARS-CoV-2 infection model with two modes of transmission and immune response[J]. Mathematical Biosciences and Engineering, 2020, 17(5): 5326-5340. doi: 10.3934/mbe.2020288

    Related Papers:

    [1] A. M. Elaiw, Raghad S. Alsulami, A. D. Hobiny . Global dynamics of IAV/SARS-CoV-2 coinfection model with eclipse phase and antibody immunity. Mathematical Biosciences and Engineering, 2023, 20(2): 3873-3917. doi: 10.3934/mbe.2023182
    [2] A. D. Al Agha, A. M. Elaiw . Global dynamics of SARS-CoV-2/malaria model with antibody immune response. Mathematical Biosciences and Engineering, 2022, 19(8): 8380-8410. doi: 10.3934/mbe.2022390
    [3] Matthew Hayden, Bryce Morrow, Wesley Yang, Jin Wang . Quantifying the role of airborne transmission in the spread of COVID-19. Mathematical Biosciences and Engineering, 2023, 20(1): 587-612. doi: 10.3934/mbe.2023027
    [4] Sarafa A. Iyaniwura, Rabiu Musa, Jude D. Kong . A generalized distributed delay model of COVID-19: An endemic model with immunity waning. Mathematical Biosciences and Engineering, 2023, 20(3): 5379-5412. doi: 10.3934/mbe.2023249
    [5] Wenhan Guo, Yixin Xie, Alan E Lopez-Hernandez, Shengjie Sun, Lin Li . Electrostatic features for nucleocapsid proteins of SARS-CoV and SARS-CoV-2. Mathematical Biosciences and Engineering, 2021, 18(3): 2372-2383. doi: 10.3934/mbe.2021120
    [6] Tahir Khan, Roman Ullah, Gul Zaman, Jehad Alzabut . A mathematical model for the dynamics of SARS-CoV-2 virus using the Caputo-Fabrizio operator. Mathematical Biosciences and Engineering, 2021, 18(5): 6095-6116. doi: 10.3934/mbe.2021305
    [7] Yangyang Yu, Yuan Liu, Shi Zhao, Daihai He . A simple model to estimate the transmissibility of the Beta, Delta, and Omicron variants of SARS-COV-2 in South Africa. Mathematical Biosciences and Engineering, 2022, 19(10): 10361-10373. doi: 10.3934/mbe.2022485
    [8] Chentong Li, Jinhu Xu, Jiawei Liu, Yicang Zhou . The within-host viral kinetics of SARS-CoV-2. Mathematical Biosciences and Engineering, 2020, 17(4): 2853-2861. doi: 10.3934/mbe.2020159
    [9] David Moreno Martos, Benjamin J. Parcell, Raluca Eftimie . Modelling the transmission of infectious diseases inside hospital bays: implications for COVID-19. Mathematical Biosciences and Engineering, 2020, 17(6): 8084-8104. doi: 10.3934/mbe.2020410
    [10] Somayeh Fouladi, Mohammad Kohandel, Brydon Eastman . A comparison and calibration of integer and fractional-order models of COVID-19 with stratified public response. Mathematical Biosciences and Engineering, 2022, 19(12): 12792-12813. doi: 10.3934/mbe.2022597
  • In this paper, we propose a new within-host model which describes the interactions between SARS-CoV-2, host pulmonary epithelial cells and cytotoxic T lymphocyte (CTL) cells. Furthermore, the proposed model takes into account the lytic and nonlytic immune responses and also incorporates both modes of transmission that are the virus-to-cell infection through extracellular environment and the cell-to-cell transmission via virological synapses. The well-posedness of the model as well as the existence of equilibria are established rigorously. Moreover, the dynamical behaviour of the model is further examined by two threshold parameters, and the biological aspects of the analytical results are further presented.


    Coronavirus disease 2019 (COVID-19) is a fatal emerging illness caused by a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. Since the first case appeared in Wuhan of China at the end of 2019, the disease has spread quickly from country to country, provoking enormous economic damage and lot of deaths worldwide. According to the World Health Organization (WHO) report of 7 June 2020 [2], SARS-CoV-2 infected 6799713 people worldwide and caused 397388 deaths.

    Recently, several mathematical models have been proposed and developed to understand the dynamics of SARS-CoV-2. However, most of these models described the propagation of the virus in human population. Therefore, the main objective of this study is to develop a within-host model that describes the interactions between SARS-CoV-2, host pulmonary epithelial cells and cytotoxic T lymphocyte (CTL) cells. This model is governed by the following nonlinear system:

    {dUdt=λdUUβ1UV1+q1Cβ2UI1+q2C,dIdt=β1UV1+q1C+β2UI1+q2CdIIpIC,dVdt=kIdVV,dCdt=σICdCC, (1.1)

    where U(t), I(t), V(t) and C(t) respectively indicate the concentration of uninfected pulmonary epithelial cells, infected pulmonary epithelial cells, free virus particles of SARS-CoV-2 and CTL cells at time t. Uninfected pulmonary epithelial cells are generated at a constant rate λ, die at rate dUU and become infected either by free virus particles at rate β1UV or by direct contact with infected pulmonary epithelial cells at rate β2UI. Both modes of infection are inhibited by nonlytic immune response at rates 1+q1C and 1+q2C, respectively. Infected pulmonary epithelial cells die at rate dII and are killed by lytic immune response at rate pIC. The biological meanings of the remaining parameters k, dV, σ and dC are respectively the production rate of virus from infected pulmonary epithelial cells, the clearance rate of virus, the immune responsiveness rate, and the death rate of CTL cells. The schematic illustration of model component interactions is given in Figure 1.

    Figure 1.  Schematic representation of model (1.1).

    In absence of immune response, model (1.1) is reduced to

    {dUdt=λdUUβ1UVβ2UI,dIdt=β1UV+β2UIdII,dVdt=kIdVV, (1.2)

    which is a special case of the model presented in [3]. Additionally, system (1.2) covers the within-host model used by Li et al. in [4] in order to estimate the parameters of SARS-CoV-2, it suffices to take β2=0 and λ=dUU(0), where U(0) is the number of uninfected epithelial cells without virus.

    In presence of immune response, model (1.1) includes the following models:

    ● Model of Nowak and Bangham [5], when both cell-to-cell mode and nonlytic immune response are ignored, i.e., β2=0 and q1=0.

    ● Model of Dhar et al. [6], when the classical virus-to-cell mode is only considered.

    The rest of this paper is organized in the following manner. In the next section, we establish some preliminary results about the well-posedness of the model, the existence of feasible biological equilibria and the uniform persistence of infection. In Section 3, we analyze the local and global asymptotic stability of equilibria by means of characteristic equation and Lyapunov functionals. Based on morphometric lungs data and virus environmental stability, the parameters estimation of the model is presented in Section 4. It is followed by numerical simulations in Section 5 to illustrate the obtained analytical results. The last section is devoted to the mathematical and biological conclusions drawn from this study.

    In this section, we determine some preliminary results such as the nonnegativity and boundedness of solutions in order to prove that our model (1.1) is biologically well-posed. Additionally, we establish the threshold parameters for the existence of feasible biological equilibria and we also discuss the uniform persistence of the proposed model.

    Theorem 2.1. All solutions of model (1.1) with initial conditions in R4+ are nonnegative and bounded.

    Proof. We have

    dUdt|U=0=λ>0,dIdt|I=0=β1UV1+q1C0 for all U,V,C0,dVdt|V=0=kI0 for all I0,dCdt|C=0=0.

    This proves that R4+ is positively invariant with regard to (1.1). Next, we establish the boundedness of solutions by considering the following function

    X(t)=U(t)+I(t)+dI2kV(t)+pσC(t).

    Hence,

    dXdt=λdUU(t)dI2I(t)dIdV2kV(t)pdCσC(t)λdX(t),

    where d=min{dU,dI2,dV,dC}. Thus,

    lim suptX(t)λd.

    Then U(t), I(t), V(t) and C(t) are bounded.

    Let U0=λdU. Obviously, the point P0(U0,0,0,0) is the unique infection-free equilibrium (1.1). Then we define the first threshold parameter which represents the basic reproduction number of model (1.1) as follows:

    R0=λ(kβ1+dVβ2)dUdIdV=R01+R02, (2.1)

    where R01=λkβ1dUdIdV is the basic reproduction number of the classical virus-to-cell mode, while R02=λβ1dUdI represents the basic reproduction number of the direct cell-to-cell mode.

    In absence of immune response and R0>1, model (1.1) has another biological equilibrium called the infection equilibrium without cellular immunity labeled by P1(U1,I1,V1,0), where

    U1=λdUR0, I1=λ(R01)dIR0, V1=kλ(R01)dIdVR0.

    In presence of immune response, the remaining biological equilibrium of (1.1) satisfies the following equations:

    I=dCσ, V=kdCσdV, C= σ(λdUU)dIdCpdC  and
    kβ1UdV(1+q1C)+β2U1+q2C=dI+pC.

    Since C0, we have UλdUdIdCσdU. This indicates that there is no biological equilibrium when U>λdUdIdCσdU or λdUdIdCσdU0. Let Y be a function defined on the closed interval [0,λdUdIdCσdU] as follows

    Y(U)=kβ1UdV(1+q1Z(U))+β2U1+q2Z(U)dIpZ(U),

    where Z(U)=σ(λdUU)dIdCpdC. We have Y(0)=σλdC<0 and

    Y(U)=kβ1(1+q1Z(U)q1UZ(U))dV(1+q1Z(U))2+β2(1+q2Z(U)q2UZ(U))(1+q2Z(U))2pZ(U).

    Since Z(U)=σdUpdC<0, we have Y(U)>0.

    When the immune response has not been established, we have from the last equation of model (1.1) that σI1dC0. Then we define the second threshold parameter which denotes the reproduction number for cellular immunity as follows

    RC1=σI1dC. (2.2)

    The biological meaning of this number is given in [7]. When RC1<1, we have I1<dCσ, U1>λdUdIdCσdU and Y(λdUdIdCσdU)<kβ1U1dV+β2U1dI=0. Then there is no equilibrium when RC1<1.

    When RC1>1, I1>dCσ, U1<λdUdIdCσdU and Y(λdUdIdCσdU)>0.

    Therefore, model (1.1) has a unique infection equilibrium with cellular immunity P2(U2,I2,V2,C2), where U2(0,λdUdIdCσdU), I2=dCσ, V2=kdCσdV and C2=σ(λdUU2)dIdCpdC.

    By applying Theorem 4.6 in [8], we can easily obtain the following result.

    Theorem 2.2. If R0>1, then model (1.1) is uniformly persistent, i.e., there exists a positive constant ε, independent of initial conditions, such that

    lim inft+U(t)ε,lim inft+I(t)ε,lim inft+V(t)ε,lim inft+C(t)ε.

    This section focuses on the stability analysis of the three equilibria P0, P1 and P2. The local stability is established by analyzing the characteristic equation. Whereas, the global stability is obtained by constructing favorable Lyapunov functionals.

    Theorem 3.1. The infection-free equilibrium P0 is globally asymptotically stable if R01 and unstable if R0>1.

    Proof. Consider the following Lyapunov functional

    L0(U,I,V,C)=U0Ψ(UU0)+I+β1U0dVV+pσC,

    where Ψ(x)=x1lnx, for x>0. It is obvious that Ψ(x)0 for all x>0, and Ψ(x)=0 if and only if x=1. Thus, L0(U,I,V,C)>0 for all U,I,V,C>0 and L0(U0,0,0,0)=0. Further, we have

    dL0dt=dUU(UU0)2+dII(kβ1U0dIdV+β2U0dI(1+q2C)1)q1β1U01+q1CVCpdCσCdUU(UU0)2+dII(R01)pdCσC.

    If R01, then dL0dt0 with equality if and only if U=U0, I=0, V=0 and C=0. By applying LaSalle's invariance principle [9], we deduce that P0 is globally asymptotically stable when R01.

    If R0>1, then the characteristic equation of model (1.1) at P0 is given by

    (dU+ξ)(dC+ξ)f0(ξ)=0, (3.1)

    where

    f0(ξ)=ξ2+(dI+dVβ2U0)ξ+dIdV(1R0).

    We have limξ+f0(ξ)=+ and f0(0)=dIdV(1R0)<0 if R0>1. Thus, the characteristic equation (3.1) has at least one positive eigenvalue when R0>1. Then P0 is unstable if R0>1.

    Next, we analyze the asymptotic stability of the two infection equilibria P1 and P2 by assuming that R0>1 and the following hypothesis

    q1(CCi)(1+q1C1+q1CiVVi)0,q2(CCi)(1+q2C1+q2CiIIi)0,(H)

    where Ii, Vi and Ci are infected pulmonary epithelial cell, virus and CTL cell components of the infection equilibrium Pi for i=1,2.

    Theorem 3.2. Suppose that (H) holds for P1. Then the infection equilibrium without cellular immunity P1 is globally asymptotically stable if RC11<R0 and unstable if RC1>1.

    Proof. Consider the following Lyapunov functional

    L1(U,I,V,C)=U1Ψ(UU1)+I1Ψ(II1)+β1U1V1kI1V1Ψ(VV1)+pσC.

    The function Ψ was used by many authors (see for example [10,11,12]). By a simple computation, we find

    dL1dt=(1U1U)(λdUU)+pdCσ(RC11)C+β1U1V1(dVV1kI1+V(1+q1C)V1IV1I1VUVI1(1+q1C)U1V1I)+β2U1I1(I(1+q2C)I1U(1+q2C)U1)+II1(β1U1V1dII1)β1U1V1kI1dVV+dII1.

    Since λ=dUU1+β1U1V1+β2U1I1=dUU1+dII1 and kI1=dVV1, we have

    dL1dt=dUU(UU1)2+pdCσ(RC11)C+β1U1V1(3U1U+V(1+q1C)V1IV1I1VUVI1(1+q1C)U1V1IVV1)+β2U1I1(2U1U+I(1+q2C)I1U(1+q2C)U1II1).

    Hence,

    dL1dt=dUU(UU1)2+pdCσ(RC11)C+β1U1V1(1VV1+V(1+q1C)V1+(1+q1C))+β2U1I1(1II1+I(1+q2C)I1+(1+q2C))+β1U1V1(4U1UIV1I1VUVI1(1+q1C)U1V1I(1+q1C))+β2U1I1(3U1UU(1+q2C)U1(1+q2C)).

    From (H), we have

    1VVi+(1+q1Ci)V(1+q1C)Vi+1+q1C1+q1Ci=q1(CCi)1+q1C(1+q1C1+q1CiVVi)0,1IIi+(1+q2Ci)I(1+q2C)Ii+1+q2C1+q2Ci=q2(CCi)1+q2C(1+q2C1+q2CiIIi)0. (3.2)

    Since the arithmetic means (AM) is greater than or equal to the geometric mean (GM), we have

    4U1UIV1I1VUVI1(1+q1C)U1V1I(1+q1C)0

    and

    3U1UU(1+q2C)U1(1+q2C)0.

    Then if RC11, we have dL1dt0 with equality if and only if U=U1, I=I1, V=V1 and C=0. It follows from LaSalle's invariance principle that P1 is globally asymptotically stable when RC11.

    It remains to show the instability of P1 when RC1>1. The characteristic equation at this equilibrium is as follows

    (σI1dCξ)f1(ξ)=0, (3.3)

    where

    f1(ξ)=|dUβ1V1β2I1ξβ2U1β1U1β1V1+β2I1β2U1dIξβ1U10kdVξ|.

    Then ξ1=σI1dC is a root of the characteristic equation (3.3). Since RC1=σI1dC>1, we get ξ1>0 which implies that the characteristic equation (3.3) has a positive root when RC1>1. Thus, P1 becomes unstable for RC1>1. This completes the proof.

    Theorem 3.3. Suppose that (H) holds for P2. Then the infection equilibrium with cellular immunity P2 is globally asymptotically stable if RC1>1.

    Proof. Construct a Lyapunov functional as follows

    L2(U,I,V,C)=U2Ψ(UU2)+I2Ψ(II2)+β1U2V2(1+q1C2)kI2V2Ψ(VV2)+pσC2Ψ(CC2).

    By using λ=dUU2+β1U2V21+q1C2+β2U2I21+q2C2=dUU2+dII2+pI2C2, I2=dCσ and kI2=dVV2, we easily get

    dL2dt=dUU(UU2)2+β1U2V21+q1C2(3U2U+(1+q1C2)V(1+q1C)V2IV2I2V(1+q1C2)UVI2(1+q1C)U2V2IVV2)+β2U2I21+q2C2(2U2U+(1+q2C2)I(1+q2C)I2(1+q2C2)U(1+q2C)U2II2).

    Thus,

    dL2dt=dUU(UU2)2+β1U2V21+q1C2(1VV2+(1+q1C2)V(1+q1C)V2+1+q1C1+q1C2)+β2U2I21+q2C2(1II2+(1+q2C2)I(1+q2C)I2+1+q2C1+q2C2)+β1U2V21+q1C2(4U2UIV2I2V(1+q1C2)UVI2(1+q1C)U2V2I1+q1C1+q1C2)+β2U2I21+q2C2(3U2U(1+q2C2)U(1+q2C)U21+q2C1+q2C2).

    Since AM is greater than or equal to GM, we have

    4U2UIV2I2V(1+q1C2)UVI2(1+q1C)U2V2I1+q1C1+q1C20,3U2U(1+q2C2)U(1+q2C)U21+q2C1+q2C20.

    By the above and (3.2), we deduce that dL2dt0 if RC1>1. It is obvious to show that dL2dt=0 if and only if U=U2, I=I2, V=V2 and C=C2. Consequently, {P2} is the largest invariant subset of {(U,I,V,C)|dL2dt=0}. From LaSalle's invariance principle, the steady state P2 is globally asymptotically stable if RC1>1.

    When we ignore the nonlytic immune response, we have q1=q2=0 and model (1.1) becomes

    {dUdt=λdUUβ1UVβ2UI,dIdt=β1UV+β2UIdIIpIC,dVdt=kIdVV,dCdt=σICdCC. (3.4)

    In this case, (H) holds. By applying Theorems 3.2 and 3.3, we have the following result.

    Corollary 3.4. Assume that R0>1.

    (ⅰ) If RC11, then P1 of model (3.4) is globally asymptotically stable.

    (ⅱ) If RC1>1, then P1 becomes unstable and P2 of model (3.4) is globally asymptotically stable.

    According to our above analytical results, model (1.1) has an unique infection-free equilibrium of the form P0(U0,0,0,0) which biologically represents the healthy state of patient without virus. Then U0=λdU is the total number of healthy pulmonary epithelial cells. In six adult human lungs, the mean alveolar number was 480 million with range 274790 million, and the range of volume lungs was 20624744 mL [13]. For eight normal lungs [14,15], the mean lung volume was 4341 mL with range 35005950 mL and the mean number of alveolar type II cells was 37±5 billion. Further, the mean lung volume was estimated to be 4340±285 mL in [16]. Based of the these morphometric data, we estimate λdU to be between 5.7757×104 and 1.2×107 cells/mL. However, the death rate of uninfected epithelial cells was estimated by Lee et al. [17] to be 103 day1. Therefore, we get λ between 57.757 and 1.2×104 cells mL1 day1.

    The median half-life of SARS-CoV-2 in aerosols was estimated to be between 1.1 and 1.2 hours with 95% credible interval [0.64,2.64], it was approximately 5.6 hours on stainless steel and 6.8 hours on plastic [18]. Then we can estimate the clearance rate dV of SARS-CoV-2 to be between 2.4464 and 15.1232 day1. It is important to note the values for dV used in [4,19] are included in our estimated range. For example, dV=10 day1 in [19].

    Based on the estimations in [4,19,20], we assume that the death rate of infected cells to be between 0.088 and 0.58 day1. We recall that the burst size is the mean number of virions produced by an infected cell during its lifespan. In the case of SARS-CoV-2, the burst size is unknown and was approximately estimated to be 103 virions [21]. Thus, we obtain k between 88 and 580 virions cell1 day1. The estimation of other parameters are summarized in Table 1.

    Table 1.  The 12 parameters of the model (1.1) with their values.
    Parameter Definition Value Source
    λ Epithelial cells 57.7571.2×104 cells mL1 day1 Calculated
    production rate
    dU Death rate of uninfected 103 day1 [17]
    epithelial cells
    β1 Virus-to-cell infection rate 01 mL virion1 day1 Assumed
    β2 Cell-to-cell infection rate 01 mL cell1 day1 Assumed
    dI Death rate of infected 0.0880.58 day1 Estimated
    epithelial cells
    k Virion production rate per 88580 virions cell1 day1 Calculated
    infected epithelial cell
    dV Virus clearance rate 2.446415.1232 day1 Estimated
    σ Activation rate of 01 mL cell1 day1 Assumed
    CTL cells
    dC Death rate of 0.051 mL cell1 day1 [5]
    CTL cells
    p Clearance rate of infection 0.051 mL cell1 day1 [5]
    q1 Non-lytic strength against 01 mL cell1 Assumed
    virus-to-cell infection
    q2 Non-lytic strength against 01 mL cell1 Assumed
    cell-to-cell infection

     | Show Table
    DownLoad: CSV

    In this section, we numerically discuss the dynamics of model (1.1) according to different parameter values.

    Based on Table 1, we choose λ=500, dU=0.001, β1=1.12×107, β2=1.1×107, q1=0.3, q2=0.6, dI=0.56, p=0.06, dV=10, dC=0.85 and the other parameters σ and k are considered as free.

    Case 1: When we take σ=0.05 and k=88, we have R0=0.97821. It follows from Theorem 3.1 that the infection-free equilibrium P0(5×105,0,0,0) is globally asymptotically stable. This theoretical result is illustrated by Figure 2 which shows the solutions of model (1.1) with different initial values tend to P0.

    Figure 2.  Dynamics of model (1.1) when R0=0.97821.

    Case 2: If σ=1.1×103 and k=230, then R0=2.3982>1 and RC1=0.67371. Figure 3 displays that the trajectories of model (1.1) with different initial values converge towards the infection equilibrium without cellular immunity P1(2.0850×105,520.5563,1.1973×104,0). This confirms that P1 is globally asymptotically stable and thus illustrates the analytical result obtained in Theorem 3.2.

    Figure 3.  Dynamics of model (1.1) when R0=2.3982>1 and RC1=0.67371.

    Case 3: When σ=4.5×103 and k=230, we get R0=2.3982>1 and RC1=2.7559>1. In Figure 4, we observe that the trajectories of model (1.1) starting from different initial conditions tend to the infection equilibrium with cellular immunity P2(3.7506×105,188.2088,4.3292×103,1.6977). This validates the global asymptotic stable of P2 given in Theorem 3.3.

    Figure 4.  Dynamics of model (1.1) when R0=2.3982>1 and RC1=2.7559>1.

    From the explicit formula of the basic reproduction number of R0 given in (2.1), we see that R0 is an increasing function with respect to k and it does not depend on σ. Also, the second threshold parameter RC1 is a increasing function with respect to k and σ (see, Figure 5).

    Figure 5.  Plot showing the relationship of k and σ with the two reproduction numbers R0 and RC1.

    In this article, we have proposed a new mathematical model to better describe the dynamics of COVID-19 in human body with virus-to-cell infection, cell-to-cell transmission, lytic and nonlytic immune responses. We have first provided the result regarding the well-posedness of the proposed model in terms of nonnegativity and boundedness of the solutions. Investigating for the biologically feasible equilibria of this SARS-CoV-2 infection model, we have obtained two threshold parameters which completely determine the dynamics of the model. The first threshold parameter called the basic reproduction number labeled by R0 and the second is the reproduction number for cellular immunity denoted by RC1. We have proved in Theorem 2.2 that the proposed model is uniformly persistent when R0>1, which biologically means that the SARS-CoV-2 persists in the host when R0>1. Further, our analytical results suggest that the infection-free equilibrium P0 is globally asymptotically stable whenever R01 (see, Theorem 3.1). This means the complete eradication of SARS-CoV-2 in human lungs. From our numerical results, this eradication of the virus and the extinction of the infection can be done after five days (see, Figure 2). However, P0 becomes unstable when R0>1 and two scenarios arise depending on the value of the reproduction number for cellular immunity RC1. When RC11, the infection equilibrium without cellular immunity P1 is globally asymptotically stable (see, Theorem 3.2). This indicates that the immune response has not been established, which causes persistence of SARS-CoV-2 in human lungs. When RC1>1, P1 becomes unstable and the infection equilibrium with cellular immunity P2 is globally asymptotically stable (see, Theorem 3.3). In this case, the virus is also persisted in the lungs because of the weak response of cellular immunity (see, Figure 4). Furthermore, we have estimated some parameters of the model based on morphometric data and virus environmental stability.

    Currently, there is no licensed drug or vaccine against COVID-19. The results of this study establish new within-host properties of SARS-CoV-2 and they can help the biologists and pharmaceutical companies to develop an effective treatment for COVID-19 that makes the patient's basic reproduction number R0 less than or equal to one, which automatically lead to the eradication of SARS-CoV-2 from the patient's lungs. Since R0 is the sum of the basic reproduction numbers for the virus-to-cell and cell-to-cell transmission modes, the last direct mode of transmission should not be ignored in the dynamics of SARS-CoV-2 infection so as not to underestimate the value of the basic reproduction number.

    We would like to thank the editor and anonymous reviewers for their constructive comments and suggestions, which have improved the quality of the manuscript.

    There is no conflicts of interest.



    [1] A. E. Gorbalenya, S. C. Baker, R. S. Baric, R. J. de Groot, C. Drosten, A. A. Gulyaeva, et al., The species severe acute respiratory syndromerelated coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2, Nat. Microbiol., 5 (2020), 536.
    [2] WHO, Coronavirus disease 2019 (COVID-19), Situation Report-139, 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200607-covid-19-sitrep-139.
    [3] K. Hattaf, N. Yousfi, Qualitative analysis of a generalized virus dynamics model with both modes of transmission and distributed delays, Int. J. Differ. Equations, 2018 (2018), 1-7.
    [4] C. Li, J. Xu, J. Liu, Y. Zhou, The within-host viral kinetics of SARS-CoV-2, Math. Biosci. Eng., 17 (2020), 2853-2861.
    [5] M. A. Nowak, C. R. Bangham, Population dynamics of immune responses to persistent viruses, Science, 272 (1996), 74-79.
    [6] M. Dhar, S. Samaddar, P. Bhattacharya, R. K. Upadhyay, Viral dynamic model with cellular immune response: A case study of HIV-1 infected humanized mice, Physica A, 524 (2019), 1-14.
    [7] K. Hattaf, Spatiotemporal dynamics of a generalized viral infection model with distributed delays and CTL immune response, Computation, 7 (2019), 1-16.
    [8] H. R. Thieme, Persistence under relaxed point-dissipativity (with application to an endemic model), SIAM J. Math. Anal., 24 (1993), 407-435.
    [9] J. P. LaSalle, The Stability of Dynamical Systems, Regional Conference Series in Applied Mathematics, SIAM Philadelphia, 1976.
    [10] P. Roop-O, W. Chinviriyasit, S. Chinviriyasit, The effect of incidence function in backward bifurcation for malaria model with temporary immunity, Math. Biosci., 265 (2015), 47-64.
    [11] C. Yang, X. Wang, D. Gao and J. Wang, Impact of awareness programs on Cholera dynamics: Two modeling approaches, Bull. Math. Biol., 79 (2017), 2109-2131.
    [12] K. Hattaf, Global stability and Hopf bifurcation of a generalized viral infection model with multidelays and humoral immunity, Physica A, 545 (2020), 123689.
    [13] M. Ochs, J. R. Nyengaard, A. Jung, L. Knudsen, M. Voigt, T. Wahlers, J. Richter, H. G. Gundersen, The number of alveoli in the human lung, Am. J. Respir. Crit. Care Med., 169 (2004), 120-124.
    [14] P. Gehr, M. Bachofen, E. R. Weibel, The normal human lung: ultrastructure and morphometric estimation of diffusion capacity, Resp. Physiol., 32 (1978), 121-140.
    [15] J. D. Crapo, B. E. Barry, P. Gehr, M. Bachofen, E. R. Weibel, Cell number and cell characteristics of the normal human lung, Am. Rev. Respir. Dis., 126 (1982), 332-337.
    [16] E. R. Weibel, What makes a good lung? The morphometric basis of lung function, Swiss Med. Wkly., 139 (2009), 375-386.
    [17] H. Y. Lee, D. J. Topham, S. Y. Park, J. Hollenbaugh, J. Treanor, T. R Mosmann, et al., Simulation and prediction of the adaptive immune response to influenza A virus infection, J. Virol., 83 (2009), 7151-7165.
    [18] N. van Doremalen, T. Bushmaker, D. H. Morris, M. G. Holbrook, A. Gamble, B. N. Williamson, et al., Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1, N. Engl. J. Med., 382 (2020), 1564-1567.
    [19] P. Czuppon, F. Débarre, A. Goncalves, O. Tenaillon, A. S. Perelson, J. Guedj, et al., Predicted success of prophylactic antiviral therapy to block or delay SARS-CoV-2 infection depends on the targeted mechanism, MedRxiv, (2020).
    [20] A. Gonçalves, J. Bertrand, R. Ke, E. Comets, X. de Lamballerie, D. Malvy, et al., Timing of antiviral treatment initiation is critical to reduce SARS-Cov-2 viral load, MedRxiv, (2020).
    [21] Y. M. Bar-On, A. Flamholz, R. Phillips, R. Milo, Science Forum: SARS-CoV-2 (COVID-19) by the numbers, Elife, 9 (2020), e57309.
  • This article has been cited by:

    1. Daniel E. Platt, Laxmi Parida, Pierre Zalloua, Lies, Gosh Darn Lies, and not enough good statistics: why epidemic model parameter estimation fails, 2021, 11, 2045-2322, 10.1038/s41598-020-79745-6
    2. Ana P. Lemos-Paião, Cristiana J. Silva, Delfim F.M. Torres, A New Compartmental Epidemiological Model for COVID-19 with a Case Study of Portugal, 2020, 44, 1476945X, 100885, 10.1016/j.ecocom.2020.100885
    3. Chandan Maji, Mayer Humi, Impact of Media-Induced Fear on the Control of COVID-19 Outbreak: A Mathematical Study, 2021, 2021, 1687-9651, 1, 10.1155/2021/2129490
    4. Mouhcine Naim, Yassine Sabbar, Mostafa Zahri, Behzad Ghanbari, Anwar Zeb, Nadia Gul, Salih Djilali, Fouad Lahmidi, The impact of dual time delay and Caputo fractional derivative on the long-run behavior of a viral system with the non-cytolytic immune hypothesis, 2022, 97, 0031-8949, 124002, 10.1088/1402-4896/ac9e7a
    5. Ahmed M. Elaiw, Raghad S. Alsulami, Aatef D. Hobiny, Modeling and Stability Analysis of Within-Host IAV/SARS-CoV-2 Coinfection with Antibody Immunity, 2022, 10, 2227-7390, 4382, 10.3390/math10224382
    6. A. M. Elaiw, Raghad S. Alsulami, A. D. Hobiny, Global dynamics of IAV/SARS-CoV-2 coinfection model with eclipse phase and antibody immunity, 2022, 20, 1551-0018, 3873, 10.3934/mbe.2023182
    7. A.M. Elaiw, A.J. Alsaedi, A.D. Hobiny, S. Aly, Stability of a delayed SARS-CoV-2 reactivation model with logistic growth and adaptive immune response, 2023, 616, 03784371, 128604, 10.1016/j.physa.2023.128604
    8. Afnan D. Al Agha, Ahmed M. Elaiw, Shaimaa A. Azoz, Esraa Ramadan, Stability analysis of within‐host SARS‐CoV‐2/HIV coinfection model, 2022, 45, 0170-4214, 11403, 10.1002/mma.8457
    9. Ahmed M. Elaiw, Raghad S. Alsulami, Aatef D. Hobiny, Dynamic Behaviors of a COVID-19 and Influenza Co-Infection Model with Time Delays and Humoral Immunity, 2023, 12, 2075-1680, 151, 10.3390/axioms12020151
    10. N. H. AlShamrani, Stability of an HTLV-HIV coinfection model with multiple delays and CTL-mediated immunity, 2021, 2021, 1687-1847, 10.1186/s13662-021-03416-7
    11. Mingjian Wang, Yuhan Hu, Libing Wu, Dynamic analysis of a SIQR epidemic model considering the interaction of environmental differences, 2022, 68, 1598-5865, 2533, 10.1007/s12190-021-01628-4
    12. Ahmed M. Elaiw, Abdulsalam S. Shflot, Aatef D. Hobiny, Global Stability of Delayed SARS-CoV-2 and HTLV-I Coinfection Models within a Host, 2022, 10, 2227-7390, 4756, 10.3390/math10244756
    13. Ahmed M. Elaiw, Abdullah J. Alsaedi, Afnan Diyab Al Agha, Aatef D. Hobiny, Global Stability of a Humoral Immunity COVID-19 Model with Logistic Growth and Delays, 2022, 10, 2227-7390, 1857, 10.3390/math10111857
    14. A.M. Elaiw, A.J. Alsaedi, A.D. Hobiny, Global stability of a delayed SARS-CoV-2 reactivation model with logistic growth, antibody immunity and general incidence rate, 2022, 61, 11100168, 12475, 10.1016/j.aej.2022.05.034
    15. Behzad Ghanbari, On fractional approaches to the dynamics of a SARS-CoV-2 infection model including singular and non-singular kernels, 2021, 28, 22113797, 104600, 10.1016/j.rinp.2021.104600
    16. Musadaq A. Hadi, Zainab M. Amean, New strategy to control covid-19 pandemic using lead/lag compensator, 2021, 68, 17468094, 102669, 10.1016/j.bspc.2021.102669
    17. Wen-Yang Li, Daqing Wang, Yuhao Guo, Hong Huang, Hongwen Zhao, Jian Kang, Wei Wang, Discriminant models for the prediction of postponed viral shedding time and disease progression in COVID-19, 2022, 22, 1471-2334, 10.1186/s12879-022-07338-x
    18. A. M. Elaiw, A. S. Shflot, A. D. Hobiny, Stability analysis of SARS-CoV-2/HTLV-I coinfection dynamics model, 2022, 8, 2473-6988, 6136, 10.3934/math.2023310
    19. Ahmed M. Elaiw, Abdulsalam S. Shflot, Aatef D. Hobiny, Shaban A. Aly, Global Dynamics of an HTLV-I and SARS-CoV-2 Co-Infection Model with Diffusion, 2023, 11, 2227-7390, 688, 10.3390/math11030688
    20. Ron Sender, Yinon M. Bar-On, Shmuel Gleizer, Biana Bernshtein, Avi Flamholz, Rob Phillips, Ron Milo, The total number and mass of SARS-CoV-2 virions, 2021, 118, 0027-8424, 10.1073/pnas.2024815118
    21. Zain Ul Abadin Zafar, Nigar Ali, Mustafa Inc, Zahir Shah, Samina Younas, Mathematical modeling of corona virus (COVID-19) and stability analysis, 2022, 1025-5842, 1, 10.1080/10255842.2022.2109020
    22. Rojhun O. Macalinao, Jcob C. Malaguit, Destiny S. Lutero, Agent-Based Modeling of COVID-19 Transmission in Philippine Classrooms, 2022, 8, 2297-4687, 10.3389/fams.2022.886082
    23. Amar Nath Chatterjee, Fahad Al Basir, Dibyendu Biswas, Teklebirhan Abraha, Global Dynamics of SARS-CoV-2 Infection with Antibody Response and the Impact of Impulsive Drug Therapy, 2022, 10, 2076-393X, 1846, 10.3390/vaccines10111846
    24. A.M. Elaiw, A.D. Al Agha, Global dynamics of SARS-CoV-2/cancer model with immune responses, 2021, 408, 00963003, 126364, 10.1016/j.amc.2021.126364
    25. T. S. Faniran, E. A. Bakare, A. O. Falade, Ali R. Ashrafi, The COVID-19 Model with Partially Recovered Carriers, 2021, 2021, 1687-0042, 1, 10.1155/2021/6406274
    26. A. M. Elaiw, A. D. Al Agha, M. A. Alshaikh, Global stability of a within-host SARS-CoV-2/cancer model with immunity and diffusion, 2022, 15, 1793-5245, 10.1142/S1793524521500935
    27. Ahmed. M. Elaiw, Abdullah J. Alsaedi, Aatef. D. Hobiny, Shaban. A. Aly, Global Properties of a Diffusive SARS-CoV-2 Infection Model with Antibody and Cytotoxic T-Lymphocyte Immune Responses, 2022, 11, 2227-7390, 190, 10.3390/math11010190
    28. Thalia Rodriguez, Hana M. Dobrovolny, Estimation of viral kinetics model parameters in young and aged SARS-CoV-2 infected macaques, 2021, 8, 2054-5703, 10.1098/rsos.202345
    29. Taye Samuel Faniran, Aatif Ali, Nawal E. Al-Hazmi, Joshua Kiddy K. Asamoah, Taher A. Nofal, Matthew O. Adewole, Dan Selişteanu, New Variant of SARS-CoV-2 Dynamics with Imperfect Vaccine, 2022, 2022, 1099-0526, 1, 10.1155/2022/1062180
    30. Khalid Hattaf, Ahmed A. Mohsen, Jamal Harraq, Naceur Achtaich, Modeling the dynamics of COVID-19 with carrier effect and environmental contamination, 2021, 12, 1793-9623, 2150048, 10.1142/S1793962321500483
    31. Khalid Hattaf, Mly Ismail El Karimi, Ahmed A. Mohsen, Zakaria Hajhouji, Majda El Younoussi, Noura Yousfi, Mathematical Modeling and Analysis of the Dynamics of RNA Viruses in Presence of Immunity and Treatment: A Case Study of SARS-CoV-2, 2023, 11, 2076-393X, 201, 10.3390/vaccines11020201
    32. Musyoka Kinyili, Justin B Munyakazi, Abdulaziz YA Mukhtar, Mathematical modeling and impact analysis of the use of COVID Alert SA app, 2021, 9, 2327-8994, 106, 10.3934/publichealth.2022009
    33. A. Sa’adah, D. A. Kamil, G. E. Setyowisnu, 2022, 2501, 0094-243X, 020004, 10.1063/5.0091002
    34. Till D. Frank, SARS-Coronavirus-2 Nonlinear Dynamics in Patients: Three-Dimensional State and Amplitude Space Descriptions, 2021, 90, 0031-9015, 073802, 10.7566/JPSJ.90.073802
    35. T D Frank, SARS-coronavirus-2 infections: biological instabilities characterized by order parameters, 2022, 19, 1478-3967, 036001, 10.1088/1478-3975/ac5155
    36. P. M. Honoré, S. Blackman, E. Perriens, 2023, Chapter 32, 978-3-031-23004-2, 441, 10.1007/978-3-031-23005-9_32
    37. Yafei Zhao, Hui Wu, Hua Cheng, Jie Lou, Model selection and identifiability analysis of HIV and SARS-CoV-2 co-infection model with drug therapy, 2023, 126, 10075704, 107501, 10.1016/j.cnsns.2023.107501
    38. M. I. El Karimi, K. Hattaf, N. Yousfi, Spatiotemporal dynamics of RNA viruses in the presence of immunity and treatment: case of SARS-CoV-2, 2024, 11, 23129794, 518, 10.23939/mmc2024.02.518
    39. L Cuesta-Herrera, F Córdova-Lepe, L Pastenes, A D Arencibia, Y Baldera-Moreno, H A Torres-Mantilla, A mathematical model and simulation scenarios for T and B cells immune response to severe acute respiratory syndrome-coronavirus-2, 2023, 2516, 1742-6588, 012007, 10.1088/1742-6596/2516/1/012007
    40. Puji Andayani, Lisa Risfana Sari, Ngatini Ngatini, 2024, 3083, 0094-243X, 040002, 10.1063/5.0224912
    41. Meng Wang, Yafei Zhao, Chen Zhang, Jie Lou, THE WITHIN-HOST VIRAL KINETICS OF SARS-COV-2, 2023, 13, 2156-907X, 2121, 10.11948/20220389
    42. QING LAN, HUI WU, JIE LOU, JIANQUAN LI, MATHEMATICAL MODELING OF INFECTION MECHANISM BETWEEN MILD AND SEVERE COVID-19 PATIENTS, 2023, 31, 0218-3390, 963, 10.1142/S021833902350033X
    43. Ahmed M. Elaiw, Amani S. Alsulami, Aatef D. Hobiny, Global properties of delayed models for SARS-CoV-2 infection mediated by ACE2 receptor with humoral immunity, 2024, 9, 2473-6988, 1046, 10.3934/math.2024052
    44. Yuhao Shou, Jie Lou, STUDIES ON THE INTERACTION MECHANISM BETWEEN THE MRNA VACCINE AGAINST SARS-COV-2 AND THE IMMUNE SYSTEM, 2024, 14, 2156-907X, 2283, 10.11948/20230365
    45. T. D. FRANK, AMPLITUDE EQUATIONS AND ORDER PARAMETERS OF HUMAN SARS-COV-2 INFECTIONS AND IMMUNE REACTIONS: A MODEL-BASED APPROACH, 2024, 27, 0219-5259, 10.1142/S0219525924500012
    46. Omar El Deeb, Antoine Matar, Impact of segregation and integration on infection dynamics: analysis of a Cholera model in a two-population system, 2024, 99, 0031-8949, 105016, 10.1088/1402-4896/ad72b4
    47. Kumama Regassa Cheneke, Abd Allah Hyder, Caputo Fractional Derivative for Analysis of COVID-19 and HIV/AIDS Transmission, 2023, 2023, 1687-0409, 1, 10.1155/2023/6371148
    48. A. El Hassani, B. Bettioui, K. Hattaf, N. Achtaich, Global dynamics of a diffusive SARS-CoV-2 model with antiviral treatment and fractional Laplacian operator, 2024, 11, 23129794, 319, 10.23939/mmc2024.01.319
    49. Hui Wu, Yafei Zhao, Xinjian Xu, Jie Lou, Modeling and analysis of a two-strain immuno-epidemiological model with reinfection, 2025, 81, 14681218, 104188, 10.1016/j.nonrwa.2024.104188
    50. Zhongwei Cao, Chenguang Guo, Zhenfeng Shi, Zhifei Song, Li Zu, Stochastic virus infection model with Ornstein–Uhlenbeck perturbation: Extinction and stationary distribution analysis, 2024, 47, 0170-4214, 7156, 10.1002/mma.9961
    51. Ledyz Cuesta-Herrera, Luis Pastenes, Ariel D. Arencibia, Fernando Córdova-Lepe, Cristhian Montoya, Dynamics of Activation and Regulation of the Immune Response to Attack by Viral Pathogens Using Mathematical Modeling, 2024, 12, 2227-7390, 2681, 10.3390/math12172681
    52. Ibrahim Nali, Attila Dénes, Global Dynamics of a Within-Host Model for Usutu Virus, 2023, 11, 2079-3197, 226, 10.3390/computation11110226
    53. Youssra Hajri, Saida Amine, Dynamics of a within-host HIV/SARS-CoV-2 co-infection model with two intracellular delays, 2025, 232, 03784754, 160, 10.1016/j.matcom.2024.12.027
  • Reader Comments
  • © 2020 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(5828) PDF downloads(401) Cited by(53)

Figures and Tables

Figures(5)  /  Tables(1)

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog